Foundation Medicine $FMI is a cancer genomics company that has held a growing position in the discussions around next-generation DNA sequencing technology, targeted cancer drug development, and genomic profiling of patient tumor samples to drive treatment decisions.
Reports of the application of FoundationOne and FoundationOne Heme assays in clinical practice are growing in the scientific literature. Therefore I have assembled this special edition of the BiotechDueDIligence Journal Watch to highlights a number of recent publications related to FMI.
Reports of the application of FoundationOne and FoundationOne Heme assays in clinical practice are growing in the scientific literature. Therefore I have assembled this special edition of the BiotechDueDIligence Journal Watch to highlights a number of recent publications related to FMI.
RSS Feed
